Microbot Medical (NASDAQ:MBOT) Stock Rating Lowered by ValuEngine
Separately, HC Wainwright reaffirmed a buy rating and set a $10.00 price objective on shares of Microbot Medical in a report on Wednesday, August 21st.
NASDAQ:MBOT traded down $0.04 during trading hours on Tuesday, hitting $6.26. The stock had a trading volume of 13,628 shares, compared to its average volume of 199,295. The company has a 50 day simple moving average of $5.99 and a two-hundred day simple moving average of $6.56. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.69 and a quick ratio of 2.69. Microbot Medical has a one year low of $1.38 and a one year high of $19.40. The firm has a market capitalization of $27.57 million, a price-to-earnings ratio of -2.60 and a beta of 5.04.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley lifted its holdings in shares of Microbot Medical by 77.0% during the 2nd quarter. Morgan Stanley now owns 6,316 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 2,748 shares during the last quarter. Geode Capital Management LLC bought a new stake in shares of Microbot Medical during the 4th quarter worth $38,000. JPMorgan Chase & Co. bought a new stake in shares of Microbot Medical during the 2nd quarter worth $45,000. BlackRock Inc. lifted its holdings in shares of Microbot Medical by 5.7% during the 2nd quarter. BlackRock Inc. now owns 183,520 shares of the biotechnology company’s stock worth $945,000 after acquiring an additional 9,906 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Microbot Medical by 5.5% during the 2nd quarter. Renaissance Technologies LLC now owns 206,887 shares of the biotechnology company’s stock worth $1,065,000 after acquiring an additional 10,838 shares during the last quarter. 14.79% of the stock is owned by institutional investors.
Microbot Medical Company Profile
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.
Further Reading: How to trade on quiet period expirations
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.